Evidence map›Paper›PMID 36668943›Full record

ArticleTropical medicine and infectious disease2023

Hematological and Clinical Features Associated with Initial Poor Treatment Outcomes in Visceral Leishmaniasis Patients with and without HIV Coinfection in Gondar, Northwest Ethiopia.

Muluneh Ademe, Yaneth Osorio, Rawliegh Howe, Saba Atnafu, Tadele Mulaw, Helina Fikre, Bruno L Travi, Asrat Hailu, Peter C Melby, Tamrat Abebe

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tropical medicine and infectious disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Muluneh AdemeDepartment of Microbiology, Immunology & Parasitology, College of Health Sciences, Addis Ababa University, Addis Ababa P.O. Box 9086, Ethiopia.
Yaneth OsorioDivision of Infectious Diseases, Department of Internal Medicine, University of Texas Medical Branch, 301 University Boulevard, Route 0435, Galveston, TX 77555, USA.
Rawliegh HoweAramuer Hanson Research Institute (AHRI), Addis Ababa P.O. Box 1005, Ethiopia.
Saba AtnafuLeishmaniasis Research and Treatment Center, University of Gondar, Gondar P.O. Box 196, Ethiopia.
Tadele MulawLeishmaniasis Research and Treatment Center, University of Gondar, Gondar P.O. Box 196, Ethiopia.
Helina FikreLeishmaniasis Research and Treatment Center, University of Gondar, Gondar P.O. Box 196, Ethiopia.
Bruno L TraviDivision of Infectious Diseases, Department of Internal Medicine, University of Texas Medical Branch, 301 University Boulevard, Route 0435, Galveston, TX 77555, USA.
Asrat HailuDepartment of Microbiology, Immunology & Parasitology, College of Health Sciences, Addis Ababa University, Addis Ababa P.O. Box 9086, Ethiopia.
Peter C MelbyDivision of Infectious Diseases, Department of Internal Medicine, University of Texas Medical Branch, 301 University Boulevard, Route 0435, Galveston, TX 77555, USA.
Tamrat AbebeDepartment of Microbiology, Immunology & Parasitology, College of Health Sciences, Addis Ababa University, Addis Ababa P.O. Box 9086, Ethiopia.
Addis Ababa University · ETThe University of Texas Medical Branch at Galveston · USUniversity of Gondar · ETArmauer Hansen Research Institute · ET

Funding

Mechanisms of Parasite Dissemination in Visceral LeishmaniasisR01AI130126 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MELBY, PETER C. · 2018 to 2022
$2.8M
NIAID NIH HHS R01 AI130126NIH HHS AI130126
6 · The paper itself

Abstract

Ethiopia is among the countries with a high leishmaniasis burden. In this retrospective review, we aimed to determine hematological and clinical features associated with initial poor treatment outcomes of visceral leishmaniasis (VL) patients. The majority of VL cases in this study had leucopenia (94.3%), thrombocytopenia (87.1%), and anemia (85.9%). HIV coinfection was present in 7.0% (n = 23) of VL cases. At the center, VL patients without HIV coinfection were treated with sodium stibogluconate and paromomycin combination, whereas HIV coinfected cases were treated with AmBisome and miltefosine combination therapy. End-of-treatment cure rates among HIV-positive and HIV-negative visceral leishmaniasis cases, respectively, were 52.2% and 96.9%. Case fatality rates were 34.8% and 2.7% in HIV-positive and HIV-negative cases, respectively. Overall, non-survivors in this study were more likely to have HIV (55.0% vs. 4.1%, p < 0.001), sepsis (15.0% vs. 1.4%, p = 0.019), and dyspnea (40.0% vs. 2.7%, p < 0.001) at admission. In this regard, particular attention to the management of superimposed disease conditions at admission, including sepsis, HIV, and dyspnea, is needed to improve VL patients’ treatment outcomes. The inadequacy of the current treatments, i.e., AmBisome and miltefosine combination therapy, for HIV coinfected visceral leishmaniasis patients requires further attention as it calls for new treatment modalities.

Indexed as

AmBisomedyspneaHIV coinfectionmiltefosinepoor outcomessepsisvisceral leishmaniasis

Identifiers

PMID36668943
PMCPMC9867226
OpenAlexW4313574552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.